HRP20190525T4 - Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe - Google Patents

Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe Download PDF

Info

Publication number
HRP20190525T4
HRP20190525T4 HRP20190525TT HRP20190525T HRP20190525T4 HR P20190525 T4 HRP20190525 T4 HR P20190525T4 HR P20190525T T HRP20190525T T HR P20190525TT HR P20190525 T HRP20190525 T HR P20190525T HR P20190525 T4 HRP20190525 T4 HR P20190525T4
Authority
HR
Croatia
Prior art keywords
promoter
vector
preparation
vaccine
ndv
Prior art date
Application number
HRP20190525TT
Other languages
English (en)
Inventor
Michel Bublot
Teshome Mebatsion
Joyce Pritchard
Perry LINZ
Original Assignee
Boehringer Ingelheim Animal Health USA Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47358292&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20190525(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Animal Health USA Inc. filed Critical Boehringer Ingelheim Animal Health USA Inc.
Publication of HRP20190525T1 publication Critical patent/HRP20190525T1/hr
Publication of HRP20190525T8 publication Critical patent/HRP20190525T8/hr
Publication of HRP20190525T4 publication Critical patent/HRP20190525T4/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/869—Herpesviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/255—Marek's disease virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/03—Herpetoviridae, e.g. pseudorabies virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • C07K14/125—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Claims (14)

1. Pripravak ili cjepivo, naznačen/o time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv virusa Newcastleske bolesti (NDV), pri čemu navedeni pripravak ili navedeno cjepivo sadrži rekombinantni vektor Gallid herpesvirusa 3 (MDV-2) soja SB-1, gdje navedeni vektor obuhvaća jedan ili više heterolognih polinukleotida koji kodiraju za ekspresiju najmanje jednog antigena i eksprimiraju najmanje jedan antigen ptičjeg patogena, dok heterologni polinukleotid kodira protein virusa Newcastleske bolesti NDV-F, pri čemu spomenuti postupak obuhvaća najmanje jednu primjenu navedenog pripravka ili cjepiva.
2. Pripravak ili cjepivo za uporabu prema patentnom zahtjevu 1, naznačen/o time, da nadalje sadrži jedan/jedno ili više pripravaka ili cjepiva odabranih iz skupine koju čine rekombinantni vektor HVT (ili MDV-3 ili Meleagrid herpesvirusa 1) koji obuhvaća heterologne polinukleotide koji kodiraju za ekspresiju najmanje jednog antigena i eksprimiraju najmanje jedan antigen ptičjeg patogena, divlji tip HVT (MDV-3), rekombinantni vektor MDV-1 (ili Gallid herpesvirusa 2) koji obuhvaća heterologne polinukleotide koji kodiraju za ekspresiju najmanje jednog antigena i eksprimiraju najmanje jedan antigen ptičjeg patogena, divlji tip MDV-1, i njihove kombinacije.
3. Pripravak ili cjepivo za uporabu prema patentnom zahtjevu 2, naznačen/o time, da rekombinantni vektor HVT jest vHVT13.
4. Pripravak ili cjepivo za uporabu prema patentnim zahtjevima 1-2, naznačen/o time, da je sekvenca proteina NDV-F najmanje 90% istovjetna sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54.
5. Pripravak ili cjepivo za uporabu prema patentnim zahtjevima 1-2, naznačen/o time, da je polinukleotid koji kodira NDV-F najmanje 90% istovjetan sekvenci SEQ ID NO: 1, 8, 49, 51 ili 53.
6. Pripravak ili cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen/o time, da je heterologni polinukleotid u Gallid herpesvirusu 3 umetnut u regiju koja kodira za glikoprotein C (UL44), regiju između ORF UL55 i ORF LORF5 u regiji unikatne duljine (UL), regiju između ORF SORF4 i ORF US10, ili unutar regije US2 od vektora Gallid herpesvirusa 3.
7. Pripravak ili cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen/o time, da rekombinantni vektor Gallid herpesvirusa 3 sadrži promotor.
8. Pripravak ili cjepivo za uporabu prema zahtjevu 7, naznačen/o time, da je promotor odabran iz skupine koju čine neposredni raniji promotor CMV, promotor zamorca CMV, promotor SV40, promotor glikoproteina X pseudorabies virusa, promotor alfa 4 herpes simpleks virusa 1, promotor glikoproteina A (ili gC) virusa Marekove bolesti, promotor glikoproteina B virusa Marekove bolesti, promotor glikoproteina E virusa Marekove bolesti, promotor glikoproteina B virusa infektivnog laringotraheitisa, promotor glikoproteina E virusa infektivnog laringotraheitisa, promotor glikoproteina D virusa infektivnog laringotraheitisa ili promotor glikoproteina I virusa infektivnog laringotraheitisa, te promotor goveđeg herpesvirusa 1.1 VP8.
9. Pripravak ili cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 1-8, naznačen/o time, da nadalje sadrži farmaceutski ili veterinarski prihvatljiv nosač, pomoćno sredstvo, prenositelj ili kemijski dodatak.
10. Rekombinantni vektor Gallid herpesvirusa 3 (MDV-2) soja SB-1, naznačen time, da sadrži heterologni polinukleotid koji kodira protein virusa Newcastleske bolesti NDV-F, promotor, i poliadenilacijski signal; pri čemu: (a) heterologni polinukleotid je polinukleotid NDV-F VIId divljeg tipa, promotor je promotor mišjeg citomegalovirusa IE (mCMV IE) i poliadenilacijski signal je poliadenilacijaski signal Simian virusa 40 (SV40), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u regiju između ORF SORF4 i ORF US10 od vektora Gallid herpesvirusa 3 (MDV-2) soja SB-1; ili (b) heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F VIId, promotor je promotor SV40 i poliadenilacijski signal je SEQ ID NO: 13, pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u regiju između ORF UL55 i ORF LORF5 u regiji unikatne duljine (UL) od vektora Gallid herpesvirusa 3 (MDV-2) soja SB-1; ili (c) heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F VIId, promotor je promotor SV40 i poliadenilacijski signal je endogeni koji potječe od gena glikoproteina C (gC), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u regiju koja kodira za glikoprotein C (UL44) od vektora Gallid herpesvirusa 3 (MDV-2) soja SB-1; ili (d) heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F V (soja CA02), promotor je promotor SV40 i poliadenilacijski signal je SEQ ID NO: 13, pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u regiju između ORF UL55 i ORF LORF5 u regiji unikatne duljine (UL) od vektora Gallid herpesvirusa 3 (MDV-2) soja SB-1; ili (e) heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F V (soja CA02), promotor je promotor SV40 i poliadenilacijski signal je endogeni koji potječe od gena glikoproteina C (gC), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u regiju koja kodira za glikoprotein C (UL44) od vektora Gallid herpesvirusa 3 (MDV-2) soja SB-1.
11. Vektor prema patentnom zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv NDV, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog pripravka ili cjepiva.
12. Pripravak ili cjepivo za uporabu prema bilo kojem od patentnih zahtjeva 1-9, ili vektor za uporabu prema patentnom zahtjevu 11, nadalje naznačeni time, da su navedeni pripravak, navedeno cjepivo ili navedeni vektor za uporabu u postupku cijepljenja životinje, pri čemu postupak obuhvaća najmanje jednu primjenu pripravka, cjepiva ili vektora.
13. Pripravak, cjepivo ili vektor za uporabu prema patentnom zahtjevu 12, naznačeni time, da postupak obuhvaća prime-boost strategiju primjene.
14. Pripravak, cjepivo ili vektor za uporabu prema bilo kojem od patentnih zahtjeva 1-9 ili 11-13, naznačeni time, da životinja je ptica.
HRP20190525TT 2011-11-30 2012-11-29 Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe HRP20190525T4 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564877P 2011-11-30 2011-11-30
US201261694957P 2012-08-30 2012-08-30
EP12805843.5A EP2785374B2 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof
PCT/US2012/067123 WO2013082317A2 (en) 2011-11-30 2012-11-29 Recombinant gallid herpesvirus 3 (mdv serotype 2) vectors expressing antigens of avian pathogens and uses thereof

Publications (3)

Publication Number Publication Date
HRP20190525T1 HRP20190525T1 (hr) 2019-05-03
HRP20190525T8 HRP20190525T8 (hr) 2023-01-20
HRP20190525T4 true HRP20190525T4 (hr) 2023-01-20

Family

ID=47358292

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20190525TT HRP20190525T4 (hr) 2011-11-30 2012-11-29 Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
HRP20192215TT HRP20192215T1 (hr) 2011-11-30 2019-12-10 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe
HRP20192241TT HRP20192241T1 (hr) 2011-11-30 2019-12-12 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20192215TT HRP20192215T1 (hr) 2011-11-30 2019-12-10 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe
HRP20192241TT HRP20192241T1 (hr) 2011-11-30 2019-12-12 Rekombinantni hvt vektori za ekspresiju antigena od ptičjih patogena i njihove uporabe

Country Status (28)

Country Link
EP (7) EP4112073A1 (hr)
JP (1) JP6149301B2 (hr)
KR (1) KR102013135B1 (hr)
CN (3) CN104159605B (hr)
AR (2) AR090401A1 (hr)
BR (1) BR112014013276B1 (hr)
CA (1) CA2857025C (hr)
CO (1) CO7061033A2 (hr)
CY (3) CY1121528T1 (hr)
DK (3) DK2785374T3 (hr)
ES (3) ES2785045T3 (hr)
HK (4) HK1197175A1 (hr)
HR (3) HRP20190525T4 (hr)
HU (3) HUE047909T2 (hr)
IN (1) IN2014CN04833A (hr)
LT (3) LT3251691T (hr)
ME (1) ME03433B (hr)
MX (2) MX361893B (hr)
PE (1) PE20141482A1 (hr)
PH (2) PH12014501174A1 (hr)
PL (3) PL2785373T3 (hr)
PT (3) PT2785373T (hr)
RS (3) RS58610B1 (hr)
RU (1) RU2620936C2 (hr)
SI (3) SI2785374T1 (hr)
UA (1) UA118651C2 (hr)
WO (2) WO2013082317A2 (hr)
ZA (1) ZA201403804B (hr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2851658C (en) 2011-10-21 2022-03-15 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
LT3251691T (lt) 2011-11-30 2020-02-10 Boehringer Ingelheim Animal Health USA Inc. Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas
EP2644702A1 (en) 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
AR097029A1 (es) 2013-07-26 2016-02-17 Intervet Int Bv Aceleración de la respuesta inmune inducida por virus vectorial en aves, composición, uso, método para la vacunación y método para acelerar la respuesta inmune
EP2845904A1 (en) * 2013-09-06 2015-03-11 Ceva Sante Animale Recombinant Marek's disease viruses and uses thereof
AR103245A1 (es) * 2014-12-24 2017-04-26 Intervet Int Bv Vacuna vectorial basada en hvt (herpes virus de los pavos) frente a nd (enfermedad de newcastle) - ibd (enfermedad de gumboro) mejorada
MX2018001815A (es) 2015-08-10 2018-09-06 Texas A & M Univ Sys Vacunas de herpesvirus de pavo recombiante y uso de las mismas.
US11596687B2 (en) 2016-06-17 2023-03-07 Intervet Inc. Recombinant non-pathogenic Marek's disease virus constructs encoding infectious laryngotracheitis virus and infectious bursal disease virus antigens
JOP20190088A1 (ar) * 2016-10-21 2019-04-21 Us Agriculture نواقل مؤتلفة للتعبير عن مولدات مضاد فيروس انفلونزا الطيور و استخداماتها
CN117357642A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
CN106929483B (zh) * 2017-01-19 2020-09-25 北京邦卓生物科技有限公司 表达鸡新城疫病毒f基因的重组火鸡疱疹病毒的构建及其应用
CN106701693A (zh) * 2017-01-19 2017-05-24 北京邦卓生物科技有限公司 表达血清ⅰ型马立克氏病病毒gb基因的重组火鸡疱疹病毒的构建及其应用
EP3391903B1 (en) * 2017-04-21 2022-02-23 The Pirbright Institute Recombinant gallid herpesvirus 3 vaccines encoding heterologous avian pathogen antigens
CN107099513B (zh) * 2017-06-22 2020-07-14 北京邦卓生物科技有限公司 一种共表达ndv hn和ibdv vp2基因的hvt的构建及其应用
CN107254450A (zh) * 2017-07-20 2017-10-17 扬州大学 克服鸡新城疫母源抗体影响的嵌合新城疫病毒疫苗载体候选株及构建方法
CN107603958A (zh) * 2017-09-29 2018-01-19 天津农学院 融合表达TM‑1基因和gD基因重组腺病毒的构建方法及重组腺病毒和应用
BR112020007213A2 (pt) * 2017-10-12 2020-10-13 Intervet International B.V. construtos de vírus da doença de marek não patogênico recombinante que codificam múltiplos antígenos heterólogos
CN111542337A (zh) 2017-12-20 2020-08-14 英特维特国际股份有限公司 用于细胞相关联的α疱疹病毒疫苗的改良稀释剂
CN108543067A (zh) * 2017-12-25 2018-09-18 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） 共表达h5亚型禽流感ha蛋白和传染性法氏囊vp2蛋白的重组火鸡疱疹病毒疫苗株
CN111918660A (zh) * 2018-01-24 2020-11-10 复诺健生物科技加拿大有限公司 重组病毒疫苗
CN109468315B (zh) * 2018-12-07 2021-09-07 袁隆平农业高科技股份有限公司 水稻耐淹基因Sub1共显性分子标记及应用
MX2021007408A (es) * 2018-12-21 2021-07-15 Ceva Sante Animale Virus del herpes aviar recombinantes que contienen multiples genes extra?os.
US11464849B2 (en) * 2019-09-11 2022-10-11 Zoetis Services Llc Recombinant herpesvirus of turkey vectors expressing antigens of avian pathogens and uses thereof
CN110872578B (zh) * 2019-11-29 2022-09-16 扬州优邦生物药品有限公司 一株变异株传染性法氏囊病毒、亚单位疫苗及其制备方法和应用
US11299517B2 (en) * 2020-04-15 2022-04-12 The United States Of America, As Represented By The Secretary Of Agriculture Recombinant vaccine against Marek's disease and Newcastle disease
EP4378474A2 (en) 2020-06-17 2024-06-05 Boehringer Ingelheim Vetmedica GmbH Recombinant hvt vectors expressing influenza hemagglutinin and immunogenic compositions, and production and uses thereof
CN112206317B (zh) * 2020-10-12 2023-09-22 浙江省淡水水产研究所 一种草鱼出血病二价核酸菌蜕疫苗的制备方法
JP2023545524A (ja) 2020-10-15 2023-10-30 セヴァ サンテ アニマレ 組換えｈｖｔ及びその使用
CN114317827B (zh) * 2022-01-07 2023-03-24 河南省农业科学院 一种鉴别不同血清型马立克病病毒感染与免疫的多重pcr引物、方法及应用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
WO1987004463A1 (en) 1986-01-27 1987-07-30 Syntro Corporation Attenuated herpesviruses, herpesviruses which include foreign dna encoding an amino acid sequence and vaccine containing same
JP2779447B2 (ja) 1988-03-20 1998-07-23 財団法人阪大微生物病研究会 弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
EP0431668B1 (en) 1989-12-04 1995-02-15 Akzo Nobel N.V. Recombinant herpesvirus of turkeys and live vector vaccines derived thereof
JP3602530B2 (ja) 1991-03-07 2004-12-15 ヴァイロジェネティクス コーポレイション 遺伝子操作したワクチン菌株
BE1004877A3 (fr) 1991-05-27 1993-02-16 Solvay Virus de l'avipox recombinant, culture de cellules infectees par ce virus et vaccins pour la volaille derives de ce virus.
US5853733A (en) 1993-02-26 1998-12-29 Syntro Corporation Recombinant herpesvirus of turkeys and uses thereof
US6183753B1 (en) 1994-08-09 2001-02-06 Schering-Plough Veterinary Corp. Recombinant chimeric virus and uses thereof
FR2719056B1 (fr) 1994-04-20 1996-09-06 Rhone Merieux Herpesvirus transformés pour exprimer gD in vitro.
CA2626498C (en) * 1994-08-09 2011-04-12 Schering-Plough Limited Recombinant chimeric virus
RU2059414C1 (ru) * 1994-12-09 1996-05-10 Государственная Курская биофабрика - Фирма "БИОК" Поливалентная вакцина для профилактики болезни марека и способ ее изготовления
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
JPH104956A (ja) * 1996-06-21 1998-01-13 Univ Michigan State マレク病ワクチン製造のための維持可能な細胞株の改良
FR2751225B1 (fr) * 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
US5980912A (en) 1997-03-25 1999-11-09 Zonagen, Inc. Chitosan induced immunopotentiation
EP1026246B1 (en) * 1997-10-03 2006-11-29 Zeon Corporation Avian infectious herpesvirus recombinants and recombinant vaccines prepared with the use of the same
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6299882B1 (en) 1999-04-09 2001-10-09 Schering Corporation UL54.5 of Marek's disease virus (MDV)
KR100354972B1 (ko) 2000-04-11 2002-10-05 대한민국 닭전염성기관지염 바이러스 ｓ1 단백질을 발현하는유전자재조합 마렉바이러스 및 그의 제조방법
US6764684B2 (en) * 2001-09-28 2004-07-20 Zeon Corporation Avian herpesvirus-based recombinant infectious bursal disease vaccine
US6866852B2 (en) 2002-01-31 2005-03-15 Zeon Corporation Recombinant herpesvirus of turkeys and use thereof
KR100801180B1 (ko) * 2006-09-26 2008-02-05 주식회사 고려비엔피 약독화된 재조합 뉴캐슬병 바이러스 및 이를 함유하는뉴캐슬병 백신
CN105567648B (zh) * 2009-04-15 2019-09-03 法国诗华大药厂 用于免疫接种水禽物种的重组禽疱疹病毒载体和疫苗
LT3251691T (lt) 2011-11-30 2020-02-10 Boehringer Ingelheim Animal Health USA Inc. Rekombinantiniai hvt vektoriai, ekspresuojantys paukščių patogenų antigenus, ir jų panaudojimas

Also Published As

Publication number Publication date
HRP20190525T8 (hr) 2023-01-20
CN104159604B (zh) 2016-08-24
RS59893B1 (sr) 2020-03-31
BR112014013276B1 (pt) 2021-07-27
WO2013082317A8 (en) 2014-07-10
ES2719409T5 (es) 2022-12-07
LT2785373T (lt) 2020-02-10
PE20141482A1 (es) 2014-11-08
BR112014013276A2 (pt) 2018-05-15
CY1122872T1 (el) 2021-05-05
WO2013082327A1 (en) 2013-06-06
PL2785374T3 (pl) 2019-07-31
CY1121528T1 (el) 2020-05-29
KR20140097515A (ko) 2014-08-06
PL2785373T3 (pl) 2020-06-01
HK1200018A1 (en) 2015-07-31
ES2785045T3 (es) 2020-10-05
ME03433B (me) 2020-01-20
EP2785374B1 (en) 2019-01-09
AR090401A1 (es) 2014-11-12
EP4112073A1 (en) 2023-01-04
DK2785373T3 (da) 2020-02-03
WO2013082327A8 (en) 2014-07-03
HK1248566A1 (zh) 2018-10-19
IN2014CN04833A (hr) 2015-09-18
RU2014126375A (ru) 2016-01-27
PL2785374T5 (pl) 2023-01-09
PL3251691T3 (pl) 2020-06-01
HRP20190525T1 (hr) 2019-05-03
EP3251691B1 (en) 2019-11-20
MX365984B (es) 2019-06-21
CN105920598A (zh) 2016-09-07
JP2015500806A (ja) 2015-01-08
PH12015502790A1 (en) 2017-07-10
EP3263130A1 (en) 2018-01-03
ES2775218T3 (es) 2020-07-24
HUE042471T2 (hu) 2019-07-29
RU2620936C2 (ru) 2017-05-30
HK1247832A1 (zh) 2018-10-05
PH12014501174B1 (en) 2014-09-08
EP3251691A1 (en) 2017-12-06
EP2785373A1 (en) 2014-10-08
EP2785374A2 (en) 2014-10-08
RS58610B1 (sr) 2019-05-31
HK1197175A1 (en) 2015-01-09
CA2857025A1 (en) 2013-06-06
CN104159605A (zh) 2014-11-19
JP6149301B2 (ja) 2017-06-21
UA118651C2 (uk) 2019-02-25
RS59892B1 (sr) 2020-03-31
CN104159604A (zh) 2014-11-19
CA2857025C (en) 2021-08-03
DK3251691T3 (da) 2020-02-10
AR089039A1 (es) 2014-07-23
CY1124618T1 (el) 2022-03-24
KR102013135B1 (ko) 2019-08-22
MX2014006361A (es) 2015-03-05
MX2014006360A (es) 2015-03-05
SI2785374T1 (sl) 2019-04-30
EP3578199A1 (en) 2019-12-11
EP3572092A1 (en) 2019-11-27
LT3251691T (lt) 2020-02-10
PT2785374T (pt) 2019-05-09
HRP20192215T1 (hr) 2020-02-21
SI2785373T1 (sl) 2020-02-28
HUE047724T2 (hu) 2020-05-28
CN104159605B (zh) 2019-04-19
WO2013082317A2 (en) 2013-06-06
SI3251691T1 (sl) 2020-02-28
PH12014501174A1 (en) 2014-09-08
HUE047909T2 (hu) 2020-05-28
PT2785373T (pt) 2020-01-27
WO2013082317A3 (en) 2013-08-15
CO7061033A2 (es) 2014-09-19
LT2785374T (lt) 2019-04-25
PT3251691T (pt) 2020-01-28
MX361893B (es) 2018-12-18
EP2785374B2 (en) 2022-08-17
ZA201403804B (en) 2015-04-29
PH12015502790B1 (en) 2017-07-10
EP2785373B1 (en) 2019-11-20
ES2719409T3 (es) 2019-07-10
HRP20192241T1 (hr) 2020-03-06
DK2785374T3 (en) 2019-04-08

Similar Documents

Publication Publication Date Title
HRP20190525T4 (hr) Rekombinantni vektori gallid herpesvirusa 3 (mdv serotip 2) koji eksprimiraju antigene ptičjih patogena i njihove uporabe
JP2015500806A5 (hr)
Hein et al. Review of poultry recombinant vector vaccines
Baron et al. Recent advances in viral vectors in veterinary vaccinology
Fuchs et al. Molecular biology of avian infectious laryngotracheitis virus
EP2419132B1 (en) Recombinant avian herpes virus vectors and vaccine for immunizing waterfowl species
Mahgoub An overview of infectious bursal disease
Herbert et al. Recombinant adenovirus expressing the haemagglutinin of peste des petits ruminants virus (PPRV) protects goats against challenge with pathogenic virus; a DIVA vaccine for PPR
HRP20221527T1 (hr) Rekombinantni hvt vektori koji eksprimiraju mnoge antigene ptičjih patogena, i cjepiva koja ih sadrže
Warimwe et al. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley fever vaccine in mice
Stading et al. Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine
RU2019115277A (ru) Рекомбинантные векторы, экспрессирующие антигены вируса птичьего гриппа, и их применения
Guo et al. Priming with a DNA vaccine and boosting with an inactivated vaccine enhance the immune response against infectious bronchitis virus
Cui et al. Avirulent Marek’s disease virus type 1 strain 814 vectored vaccine expressing avian influenza (AI) virus H5 haemagglutinin induced better protection than turkey herpesvirus vectored AI vaccine
RU2014120471A (ru) Конструкции рекомбинантного непатогенного вируса болезни марека, кодирующие антигены вируса инфекционного ларинготрахеита и вируса болезни ньюкасла
KR20200002834A (ko) 이종 조류 병원체 항원을 암호화하는 재조합 갈리드 헤르페스바이러스 3형 백신
Ramos et al. Avian CD154 enhances humoral and cellular immune responses induced by an adenovirus vector-based vaccine in chickens
Zeshan et al. Protective immune responses induced by in ovo immunization with recombinant adenoviruses expressing spike (S1) glycoprotein of infectious bronchitis virus fused/co-administered with granulocyte-macrophage colony stimulating factor
CN118308379A (zh) 爱泼斯坦-巴尔病毒抗原构建体
Guo et al. Recombinant infectious hematopoietic necrosis virus expressing infectious pancreatic necrosis virus VP2 protein induces immunity against both pathogens
Wernike et al. N-terminal domain of Schmallenberg virus envelope protein Gc delivered by recombinant equine herpesvirus type 1 and modified vaccinia virus Ankara: Immunogenicity and protective efficacy in cattle
CA2417923A1 (en) Vaccination against host cell-associated herpesviruses
Lorenzo et al. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep
Pavlova et al. Identification and functional analysis of membrane proteins gD, gE, gI, and pUS9 of Infectious laryngotracheitis virus
Zanetti et al. Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens